文献速递中毒与环境急症创伤与烧伤

重大创伤患者尿液药物筛查假阴性率及类型与确证毒理学检测的比较

Rates and types of urine drug screen false negative results compared with confirmatory toxicology testing in major trauma patients.
PubMed 文献 · Clin Toxicol (Phila) · 2022-09-07
一句话结论创伤患者常规尿液药物筛查对精神活性及非精神活性物质假阴性常见,作者建议扩大SBIRT范围纳入烟草、处方镇痛药和非处方抗组胺药。

本研究为前瞻性队列研究,对成人创伤及烧伤激活患者的去标识尿液样本同时进行尿液药物筛查(UDS)和LC-MS全面检测(>200种分析物),比较假阴性类型与发生率。100份样本中,56份检出精神活性物质假阴性(最常见为抗惊厥药,主要为加巴喷丁N=13),70份检出非精神活性物质假阴性(最常见为尼古丁N=33)。UDS覆盖的物质类别中,阿片类假阴性率25%、苯丙胺类5%、阿片剂3%。可卡因(p=0.015)和大麻素(p=0.002)与伤害意图显著相关。作者认为常规UDS假阴性常见,建议扩大SBIRT范围。

要点

  • 100份创伤/烧伤患者尿样中,56份存在精神活性物质UDS假阴性,最常见为抗惊厥药(主要为加巴喷丁N=13)、阿片受体激动剂(N=12)、抗组胺药(主要为苯海拉明N=10)、苯乙胺类(主要为安非他酮N=5)。
  • 非精神活性物质假阴性见于70/100份样本,最常见为尼古丁(N=33)、咖啡因(N=23)、对乙酰氨基酚(N=22)、抗抑郁药(N=12)。
  • UDS覆盖且LC-MS同时检测的物质类别中,假阴性率分别为阿片剂3%、苯丙胺类5%、阿片类药物25%。
  • 可卡因(p=0.015)和大麻素(p=0.002)与伤害意图(自伤/他伤 vs 意外伤)显著相关。
  • 作者建议在创伤患者中扩大SBIRT,纳入烟草产品、处方镇痛药和非处方抗组胺药的滥用筛查。

适用人群与场景

  • 成人创伤及烧伤激活患者的去标识尿液样本,来自前瞻性队列研究。

研究设计与关键结果

  • 研究类型:前瞻性队列研究,样本量100份尿液样本,成人创伤及烧伤激活患者。
  • 干预与对照:所有样本同时进行UDS和LC-MS全面检测(>200种分析物),医源性药物不计入假阴性。
  • 主要终点:精神活性物质假阴性56/100份,非精神活性物质假阴性70/100份。
  • UDS覆盖物质类别的假阴性率:阿片剂3%、苯丙胺类5%、阿片类药物25%。
  • 伤害意图分析:可卡因(p=0.015)和大麻素(p=0.002)与伤害意图显著相关;老年患者多重用药与跌倒伤相关。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者建议在创伤患者中扩大SBIRT,纳入烟草产品、处方镇痛药和非处方抗组胺药的滥用筛查。
  • 常规UDS可能低估精神活性及非精神活性物质暴露,尤其对加巴喷丁、苯海拉明、安非他酮、尼古丁、咖啡因、对乙酰氨基酚和抗抑郁药。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Trauma centers are required to screen patients for alcohol use, and if necessary, intervene and refer to treatment (SBIRT). Similar screening for illicit drug use is recommended but not required. Urine drug screening (UDS) underestimates problematic substance use. This study aimed to estimate the types and rates of UDS false negatives (FN) compared to comprehensive testing by liquid chromatography-mass spectrometry (LC-MS) in trauma patients.

METHODS: We performed a prospective cohort study of deidentified urine samples from adult trauma and burn activation patients. Both UDS and LC-MS comprehensive testing of >200 analytes were performed by a reference laboratory on all samples. Iatrogenic medications were excluded from the FN count. Crosstab analyses were conducted for UDS versus LC-MS outcomes to establish FN types and rates. We dichotomized the results by creating an "intentionality" variable (intentional injuries by self/others versus accidental injuries). A series of crosstabs with odds ratios considered intentionality by substance class and demographics. Statistically significant variables by Chi-Square were assessed by logistic regression.

RESULTS: Psychoactive FN were detected in 56/100 urine samples analyzed; the most frequent included anticonvulsants (primarily gabapentin, N = 13), opioid agonists (N = 12), antihistamines (primarily diphenhydramine, N = 10), and phenethylamines (primarily bupropion, N = 5). Nonpsychoactive FN were detected in 70/100 samples; the most common were nicotine (N = 33), caffeine (N = 23), acetaminophen (N = 22), and antidepressants (N = 12). Of substance classes included in the UDS and also tested by LC-MS, FN occurred for opiates (3%), amphetamines (5%) and opioids (25%). Polypharmacy was associated with fall injuries in elderly patients. Cocaine (p = 0.015) and cannabinoids (p = 0.002) were significantly associated with intentionality.

CONCLUSIONS: Our results indicate that FN for potentially important psychoactive and nonpsychoactive substances are common when toxicologic testing is limited to routine UDS in trauma patients. We recommend expanding SBIRT in this patient population to include misuse of tobacco products, prescription analgesics, and over-the-counter antihistamines.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Weiss ST, Veach LJ, McGill W, et al. Rates and types of urine drug screen false negative results compared with confirmatory toxicology testing in major trauma patients. Clin Toxicol (Phila). 2022. PMID: 36069771. doi:10.1080/15563650.2022.2117052

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。